KR910012244A - 톡소플라스마 곤디 항원, 이의 제조방법 및 이의 용도 - Google Patents

톡소플라스마 곤디 항원, 이의 제조방법 및 이의 용도 Download PDF

Info

Publication number
KR910012244A
KR910012244A KR1019900020155A KR900020155A KR910012244A KR 910012244 A KR910012244 A KR 910012244A KR 1019900020155 A KR1019900020155 A KR 1019900020155A KR 900020155 A KR900020155 A KR 900020155A KR 910012244 A KR910012244 A KR 910012244A
Authority
KR
South Korea
Prior art keywords
protein
nucleic acid
acid sequence
antigen
preparation
Prior art date
Application number
KR1019900020155A
Other languages
English (en)
Other versions
KR100215607B1 (ko
Inventor
크나프 스테판
지겔마이어 로베르트
퀴퍼 한스
Original Assignee
스타인, 부그
베링베르케 아크티엔게젤샤프트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 스타인, 부그, 베링베르케 아크티엔게젤샤프트 filed Critical 스타인, 부그
Publication of KR910012244A publication Critical patent/KR910012244A/ko
Priority to KR1019980056654A priority Critical patent/KR100215606B1/ko
Application granted granted Critical
Publication of KR100215607B1 publication Critical patent/KR100215607B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/45—Toxoplasma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/20—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

내용 없음

Description

톡소플라스마 곤디 항원, 이의 제조방법 및 이의 용도
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (13)

  1. 표 1 내지 11에 따른 아미노산 서열을 포함하거나 상기 표의 DNA 서열에 의해 암호화되는 단백질 또는 이의 면역원성 부분.
  2. 제1항에서 청구된 단밸질을 암호화하는 핵산 서열.
  3. 제2항에서 청구된 핵산 서열을 포함하는 플라즈미드.
  4. 제3항에서 청구된 프라즈미드로 형질전화된 원핵 또는 진핵 세포.
  5. 제1항에서 청구된 단백질에 대한 모노클로날 또는 폴리클로날 항체.
  6. 제3항에서 청구된, 삽입된 DNA를 발현하는 플라즈미드로 원핵 또는 진핵 세포를 형질전화시키고, 발현 생성물을 분리함을 포함하는, 제1항에서 청구된 단백질의 제조방법.
  7. 제1항에서 청구된 단백질을 포함하는 톡소플라스마병 감염을 탐침하는 진단법.
  8. 제1항에서 청구된 단백질을 하나 이상 포함하는 백신.
  9. 제2항에서 청구된 핵산 서열을 포함하는 진단법.
  10. 제5항에서 청구된 항체를 포함하는 진단법.
  11. 제7항에있어서, 각 경우 P35 및 /또는 P68또는 상기 단백질의 면역원성 부분을 포함하는 진단법.
  12. 시험 체액을 제7항 또는 제11항에서 청구된 진단에 대해 시험함을 특징으로 하는, 톡소플라스마병 감염의 탐침방법.
  13. 톡소플라스마병 감염을 탐침하기 위한 제1항에서 청구된 단백질, 또는 제2항에서 청구된 핵산 서열 또는 제5항에서 청구된 항체의 용도.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019900020155A 1989-12-08 1990-12-08 툭소플라스마곤디 항원,이의 제조 방법 및 이를 포함하는 진단제 KR100215607B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1019980056654A KR100215606B1 (en) 1989-12-08 1998-12-21 Toxoplasma gondii antigens, the preparation thereof and the diagnostic agent containing them

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE3940598A DE3940598A1 (de) 1989-12-08 1989-12-08 Toxoplasma gondii-antigene, ihre herstellung und ihre verwendung
DEP39405982 1989-12-08
DE39405982 1989-12-08

Publications (2)

Publication Number Publication Date
KR910012244A true KR910012244A (ko) 1991-08-07
KR100215607B1 KR100215607B1 (ko) 1999-08-16

Family

ID=6395070

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1019900020155A KR100215607B1 (ko) 1989-12-08 1990-12-08 툭소플라스마곤디 항원,이의 제조 방법 및 이를 포함하는 진단제
KR1019980056654A KR100215606B1 (en) 1989-12-08 1998-12-21 Toxoplasma gondii antigens, the preparation thereof and the diagnostic agent containing them

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1019980056654A KR100215606B1 (en) 1989-12-08 1998-12-21 Toxoplasma gondii antigens, the preparation thereof and the diagnostic agent containing them

Country Status (13)

Country Link
US (3) US6022546A (ko)
EP (4) EP0431541B1 (ko)
JP (4) JP3085972B2 (ko)
KR (2) KR100215607B1 (ko)
AT (4) ATE206435T1 (ko)
AU (1) AU629074B2 (ko)
CA (1) CA2031811C (ko)
DE (5) DE3940598A1 (ko)
DK (1) DK0431541T3 (ko)
ES (4) ES2152357T3 (ko)
GR (1) GR3020819T3 (ko)
IE (1) IE75375B1 (ko)
PT (1) PT96097B (ko)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992002624A1 (en) * 1990-08-10 1992-02-20 The Flinders University Of South Australia Cloning and expression of toxoplasma antigens and use of recombinant antigens
GB9027728D0 (en) * 1990-12-20 1991-02-13 Smithkline Beecham Biolog Novel protein
FR2692282B1 (fr) * 1992-06-15 1995-07-13 Pasteur Institut Clonage du gene codant pour la proteine gp28.5 de t. gondii; fragments peptidiques issus de ladite proteine et leurs applications.
AU6172194A (en) * 1993-02-08 1994-08-29 Paravax, Inc. Defective sindbis virus vectors that express (toxoplasma gondii) p30 antigens
ZA958366B (en) * 1994-10-06 1996-04-24 Akzo Nobel Nv New toxoplasma gondii antigens
WO1997027300A1 (en) * 1996-01-26 1997-07-31 Innogenetics N.V. TOXOPLASMA GONDII ANTIGEN Tg20
EP0953641A3 (en) * 1998-03-26 2002-03-13 Pfizer Products Inc. Polynucleotide molecules encoding neospora proteins
AU2006202355B2 (en) * 1998-05-01 2009-08-20 Glaxosmithkline Biologicals Sa Neisseria meningitidis antigens and compositions
US6329157B1 (en) 1998-05-28 2001-12-11 Abbott Laboratories Antigen cocktails and uses thereof
WO1999061906A2 (en) * 1998-05-28 1999-12-02 Abbott Laboratories Toxoplasma gondii antigens, p35, and uses thereof
AU4825699A (en) * 1998-06-19 2000-01-05 Genzyme Corporation Identification and use of differentially expressed genes and polynucleotide sequences
BR0308620A (pt) * 2002-03-21 2005-02-15 Kenton S R L Fragmentos de antìgenos para a diagnose de toxoplasma gondii
US7094879B2 (en) 2002-10-02 2006-08-22 Abbott Laboratories Genetically engineered P30 antigen, improved antigen cocktail, and uses thereof
JP4292847B2 (ja) 2003-03-31 2009-07-08 マツダ株式会社 車両のリアバンパー構造
JP2008535481A (ja) 2005-03-08 2008-09-04 ケントン・ソシエタ・ア・レスポンサビリタ・リミタータ Ｔｏｘｏｐｌａｓｍａｇｏｎｄｉｉのキメラ組換え抗原
US7432046B2 (en) 2005-11-02 2008-10-07 Abbott Laboratories Methods for the determination of antibody IgG avidity
US9182398B2 (en) 2006-04-01 2015-11-10 Medical Service Consultation International, Llc Methods and compositions for detecting fungi and mycotoxins
US20100068718A1 (en) 2008-08-22 2010-03-18 Hooper Dennis G Methods and Compositions for Identifying Yeast
CN103517714A (zh) * 2010-12-23 2014-01-15 英珀特疗法有限公司 用于刚地弓形虫感染和弓形体病的诊断和治疗的方法和蛋白抗原组合物
CN102313811A (zh) * 2011-09-19 2012-01-11 厦门市仙岳医院 弓形虫IgG抗体胶体金免疫层析检测试剂条及制备方法
CN102305861B (zh) * 2011-09-19 2014-06-18 厦门大学附属中山医院 弓形虫IgM与IgG抗体联合检测试剂条及其制备方法
CN103235119B (zh) * 2013-04-11 2015-09-16 南京农业大学 一种用于弓形虫感染的诊断抗原的应用
KR101682406B1 (ko) * 2016-08-12 2016-12-05 신영기술개발(주) 교량 선배수관 시공방법
CN111116726A (zh) * 2020-01-14 2020-05-08 中国农业科学院北京畜牧兽医研究所 用于检测弓形虫的重组蛋白及其编码基因
CN111265659A (zh) * 2020-02-28 2020-06-12 南京农业大学 一种刚地弓形虫纳米材料亚单位疫苗及其制备方法和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2618680B1 (fr) * 1987-07-31 1990-05-11 Pasteur Institut Antigenes d'excretion-secretion specifiques de toxoplasma gondii, leurs produits d'expression, leur procede d'obtention et leurs applications diagnostiques et prophylactiques
FR2625099B1 (fr) * 1987-12-24 1991-06-14 Transgene Sa Proteines et leur procede de preparation, sequences d'adn, anticorps et leur application, poxvirus, cellules transformees ou infectees et compositions pharmaceutiques utiles dans la prevention de la toxoplasmose
US4877726A (en) * 1988-03-02 1989-10-31 Research Institute Of Palo Alto Medical Foundation Method for the detection of acute-phase toxoplasma infection
US5429922A (en) * 1988-03-09 1995-07-04 The Board Of Trustees Of The Leland Stanford Junior University Composition and method for distinguishing virulent and non-virulent toxoplasma infections
JPH02503633A (ja) * 1988-03-09 1990-11-01 ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ トキソプラスマ症のための診断上の遺伝子

Also Published As

Publication number Publication date
JP3085972B2 (ja) 2000-09-11
ATE141289T1 (de) 1996-08-15
AU629074B2 (en) 1992-09-24
JP3366628B2 (ja) 2003-01-14
PT96097B (pt) 1998-02-27
ES2092483T3 (es) 1996-12-01
US6326008B1 (en) 2001-12-04
JP2000308495A (ja) 2000-11-07
US6419925B1 (en) 2002-07-16
KR100215606B1 (en) 1999-08-16
ATE206435T1 (de) 2001-10-15
DE59010450D1 (de) 1996-09-19
DE59010925D1 (de) 2001-11-08
EP0748815A1 (de) 1996-12-18
EP0751147A1 (de) 1997-01-02
EP0431541B1 (de) 1996-08-14
PT96097A (pt) 1991-09-30
ES2152357T3 (es) 2001-02-01
JP2002010793A (ja) 2002-01-15
DE59010915D1 (de) 2000-11-23
ES2149913T3 (es) 2000-11-16
DE3940598A1 (de) 1991-06-13
JP3390749B2 (ja) 2003-03-31
DK0431541T3 (da) 1997-01-06
EP0431541A3 (en) 1992-04-22
EP0751147B1 (de) 2000-09-06
ATE197068T1 (de) 2000-11-15
JP3245143B2 (ja) 2002-01-07
IE904426A1 (en) 1991-06-19
KR100215607B1 (ko) 1999-08-16
CA2031811A1 (en) 1991-06-09
ES2161817T3 (es) 2001-12-16
DE59010913D1 (de) 2000-10-12
ATE196162T1 (de) 2000-09-15
GR3020819T3 (en) 1996-11-30
JP2002010794A (ja) 2002-01-15
EP0431541A2 (de) 1991-06-12
EP0748816A1 (de) 1996-12-18
IE75375B1 (en) 1997-09-10
AU6781990A (en) 1991-06-13
EP0748815B1 (de) 2001-10-04
EP0748816B1 (de) 2000-10-18
JPH03197497A (ja) 1991-08-28
CA2031811C (en) 2003-05-06
US6022546A (en) 2000-02-08

Similar Documents

Publication Publication Date Title
KR910012244A (ko) 톡소플라스마 곤디 항원, 이의 제조방법 및 이의 용도
DK0942983T3 (da) Streptococcus pneumoniae-antigener og -vacciner
DE3750342T2 (de) Menschliches gamma-interferon-spezifisches Rezeptorprotein, Antikörper gegen dieses Protein, Verfahren zur Herstellung dieses Proteins und dieses Antikörpers und dieses Protein und diesen Antikörper enthaltende Zusammensetzungen.
CA2131826A1 (en) MN Gene and Protein
KR840003420A (ko) 왁진 조성물
EP1318401B9 (de) Verfahren zur Früherkennung der Serokonversion eines gegen Hepatitis C-Virus gerichteten Antikörpers
ES2144399T3 (es) Clonado del adn de virus de anemia de los pollos.
ES553757A0 (es) Un metodo para preparar proteinas que son inmunologicamente reactivas con anticuerpos para virus asociados con linfadenopatia
RU97100934A (ru) Нуклеотидные последовательности пестивирусных штаммов, полипептиды, закодированные этими последовательностями, и их использование для диагностики и профилактики пестивирусных инфекций
DE69638024D1 (de) Melanoma antigene p15 und deren anwendung in diagnostischen und therapeutischen verfahren
BR9709958A (pt) Polipeptídeos capaz de formar estruturas de ligaçãode antígeno com especificidade para os antígenos de rhesus d o dna que os codifica e o processo para sua preparação e uso
DE3650011D1 (de) EXPRESSION UND DIAGNOSE MIT gag-KODIERTEN PEPTIDEN, DIE MIT ANTIKÖRPERN GEGEN LAV IMMUNOLOGISCH REAKTIV SIND.
Gerencser et al. Serological identification of Actinomyces using fluorescent antibody techniques
Aronstein et al. Identification of species-specific and gender-specific proteins and glycoproteins of three human schistosomes
EP0869177A3 (en) Human a- and b- platelet-derived growth factor receptor proteins and uses therefor.
EP0293827A3 (en) Assay for leishmaniasis
ES2005753A6 (es) Procedimiento para la preparacion de polipeptidos inmunologicamente activos utiles para la obtencion de vacunas antimalaria y para la deteccion de enfermedades paludicas.
KR890008318A (ko) 플라스모듐 팔시파룸의 재조합 히스티딘-고함유 단백질, 이의 제조방법 및 용도
KR890008316A (ko) 항응고성 단백질 pp4-x, 및 이의 제조방법 및 용도
KR930703445A (ko) 톡소플라스마 곤디(toxoplasma gondii)의 단백질 항원의 클로닝 및 발현
Bauer Immunological investigations on the evolution of fibrinogen and plasminogen
BR9905780A (pt) Antìgenos vacinais de leptospira para prevenção da laptospirose
Bopp et al. Comparative studies on novel protein antigens of streptococci of the serological group B
Stott Protein blotting: Baldo, BA and Tovey, ER (Eds.) viii+ 168 pp. Karger, Basel, 1989. GBP 50.90 ISBN 3-8055-4881-8
Amsterdam et al. Diagnostic technologies in clinical microbiology: Introduction and overview.

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
N231 Notification of change of applicant
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20100413

Year of fee payment: 12

EXPY Expiration of term